Behrad Derakhshan, Ph.D.

Behrad Derakhshan, Ph.D., Chief Business Officer

Behrad Derakhshan, Ph.D. has served as Chief Business Officer since September 2020 and is responsible for our corporate strategy and business development. Dr. Derakhshan brings more than 10 years of experience in the rare/ultra-rare disease space. Most recently, Dr. Derakhshan served as Chief Business Officer at VectivBio, a clinical-stage biotechnology company focused on developing novel therapeutics across a variety of rare conditions where he was responsible for the company’s capital formation and business development strategy. Dr. Derakhshan previously served as the Head of Business Development at Therachon, a biotechnology company focused on the discovery and development of therapeutics for rare pediatric conditions until its acquisition by Pfizer Inc. in 2019. Prior to Therachon, he was a Director at Alexion Pharmaceuticals responsible for Business Development and Strategic Evaluation after initially leading the New Products Global Commercial Insights and Analytics team. Earlier in his career, Dr. Derakhshan worked in management consulting, first as a Senior Consultant at Easton Associates and then as an Associate Director at Navigant Consulting. During that time, he advised a number of global pharmaceutical and biotechnology companies across a range of strategic projects. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in Biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK. He received a First-Class Honors BSc. with distinction in Biochemistry from the University of Surrey.